In a report released today, Michael Ryskin from Bank of America Securities reiterated a Buy rating on Stevanato Group (STVN – Research Report), with a price target of $29.00. The company’s shares opened today at $21.00.
According to TipRanks, Ryskin is a 4-star analyst with an average return of 5.8% and a 59.81% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Illumina, Zoetis, and Bruker.
Currently, the analyst consensus on Stevanato Group is a Moderate Buy with an average price target of $35.00.
The company has a one-year high of $36.30 and a one-year low of $20.01. Currently, Stevanato Group has an average volume of 472.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stevanato Group (STVN) Company Description:
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages.
Read More on STVN:
